Study PI3K as a Key Target in Glioblastoma
Time: 2:15 pm
day: Day Two
Details:
- Explore opportunities and challenges associated with modulating PI3K
as a therapeutic strategy in glioblastoma - Examine The significance of biomarkers in patient selection
- Review emerging clinical data from paxalisib, a brain penetrant PI3K /
mTOR inhibitor